Pharmacophore-based virtual screening: a review of recent applications
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
IMPORTANCE OF THE FIELD: In research relating to the development of new drugs, hit identification and validations are critical for successful optimization of candidates. To achieve rapid identification of new lead compounds, high-throughput screening assays have been employed in many pharmaceutical companies and laboratories. However, their success depends on the assay system relevant to in vivo conditions and they are physically limited by the repertoire of compounds. As an alternative or complementary approach to high-throughput screening assays, virtual screening is an efficient method to identify drug candidates in silico from large chemical compound databases. Its usefulness has been verified by current applications that successfully retrieved hit and lead identifications against various disease targets. However, for better application, the scoring functions for distinguishing possible active and inactive compounds must beimproved. AREAS COVERED IN THIS REVIEW: In this review, we provide an overview of pharmacophore-based virtual screening methods with a special focus on their successful application towards finding hits against various diseasetargets. WHAT THE READER WILL GAIN: Readers will rapidly gain insight into the recent successful applications of pharmacophore-based virtual screening. They will acknowledge that this technique is a powerful and cost-effective alternative to high-throughput assays. TAKE HOME MESSAGE: Although there are many hurdles yet to be resolved, virtual screening techniques will emerge as essential infrastructure and as a prerequisite for developing new lead compounds with therapeuticapplications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ZINC − A Free Database of Commercially Available Compounds for Virtual Screening
Irwin, J. J., & Shoichet, B. K. (2005) · Journal of Chemical Information and Modeling · doi:10.1021/ci049714+ · Cited by 4,058 · cited 1×
“[88] successfully discovered novel FFAR1 agonists and antagonists through pharmacophore-based virtual screening by using the set of drug-like compounds retrieved from the ZINC database [89] of ~ 2.”
MethodThe DNA damage response: putting checkpoints in perspective
Zhou, B.-B. S., & Elledge, S. J. (2000) · Nature · doi:10.1038/35044005 · Cited by 3,213
Free fatty acids regulate insulin secretion from pancreatic β cells through GPR40
Itoh, Y., Kawamata, Y., Harada, M., Kobayashi, M., Fujii, R., Fukusumi, S., Ogi, K., Hosoya, M., Tanaka, Y., Uejima, H., et al. (2003) · Nature · doi:10.1038/nature01478 · Cited by 1,538 · cited 1×
“This receptor is highly expressed in the beta cells of pancreatic islets, and its activation by long-chain free fatty acids is known to enhance glucose-stimulated insulin secretion [87] .”
BackgroundDiagnosis and complications of Cushing’s syndrome: a consensus statement
Arnaldi, G., Angeli, A., Atkinson, A. B., Bertagna, X., Cavagnini, F., Chrousos, G. P., Fava, G. A., Findling, J. W., Gaillard, R. C., Grossman, A. B., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030871 · Cited by 1,362 · cited 1×
“A physiological excess of glucocorticoids causes metabolic abnormalities such as obesity, impaired glucose tolerance, atherosclerosis, dyslipidemia and hyperglycemia [67,68] .”
BackgroundMolecular recognition of fatty acids by peroxisome proliferator-activated receptors
Xu, H. E., Lambert, M. H., Montana, V. G., Parks, D. J., Blanchard, S. G., Brown, P. J., Sternbach, D. D., Lehmann, J. M., Wisely, G. B., Willson, T. M., et al. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80467-0 · Cited by 1,169
Cited by
Sabe, V. T., Ntombela, T., Jhamba, L. A., Maguire, G. E. M., Govender, T., Naicker, T., & Kruger, H. G. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113705 · Cited by 625
Artificial Intelligence and Machine Learning Technology Driven Modern Drug Discovery and Development
Sarkar, C., Das, B., Rawat, V. S., Wahlang, J. B., Nongpiur, A., Tiewsoh, I., Lyngdoh, N. M., Das, D., Bidarolli, M., & Sony, H. T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032026 · Cited by 347
“Virtual screening approaches consist of docking-based, pharmacophore-based [88], similarity searching [89], and ML schemes [90].”
Artificial intelligence in drug design
Zhong, F., Xing, J., Li, X., Liu, X., Fu, Z., Xiong, Z., Lu, D., Wu, X., Zhao, J., Tan, X., et al. (2018) · Science China Life Sciences · doi:10.1007/s11427-018-9342-2 · Cited by 259
eToxPred: a machine learning-based approach to estimate the toxicity of drug candidates
Pu, L., Naderi, M., Liu, T., Wu, H.-C., Mukhopadhyay, S., & Brylinski, M. (2019) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-018-0282-6 · Cited by 212
“Although the combination of pharmacophore modeling, QSAR, and VS techniques has been demonstrated to be valuable in the absence of the protein structure data [12, 13], the three-dimensional (3D) information on the target protein allows employing structure-based drug design (SBDD) [14] in CADD.”
MethodDiffDec: Structure-Aware Scaffold Decoration with an End-to-End Diffusion Model
Xie, J., Chen, S., Lei, J., & Yang, Y. (2024) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c01466 · Cited by 31
Metadata
- Authors
- Kim, K.-H., Kim, N. D., & Seong, B.-L.
- Venue
- Expert Opinion on Drug Discovery
- Publisher
- Informa Healthcare
- Published
- 2010-01-27
- Volume
- 5
- Issue
- 3
- Pages
- 205-222
- ISSN
- 1746-0441 (ISSN-L)
- 1746-045X
- OpenAlex
- W2122856363
- Cited by
- 89
- References
- 5
- FWCI
- 6.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacophore-based virtual screening: a review of recent applications. https://app.cochat.ai/papers/10.1517/17460441003592072
- The paper
- Kim, K.-H., Kim, N. D., & Seong, B.-L. (2010). Pharmacophore-based virtual screening: a review of recent applications. Expert Opinion on Drug Discovery. https://doi.org/10.1517/17460441003592072
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.